Contrasting CollPlant Biotechnologies (NASDAQ:CLGN) and Pathfinder Cell Therapy (OTCMKTS:PFND)

CollPlant Biotechnologies (NASDAQ:CLGN) and Pathfinder Cell Therapy (OTCMKTS:PFND) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, earnings, institutional ownership, analyst recommendations and dividends.

Institutional and Insider Ownership

21.7% of CollPlant Biotechnologies shares are held by institutional investors. 9.6% of CollPlant Biotechnologies shares are held by company insiders. Comparatively, 15.1% of Pathfinder Cell Therapy shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for CollPlant Biotechnologies and Pathfinder Cell Therapy, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CollPlant Biotechnologies	0	0	2	1	3.33
Pathfinder Cell Therapy	0	0	0	0	0.00

CollPlant Biotechnologies presently has a consensus price target of $12.50, indicating a potential upside of 207.43%. Given CollPlant Biotechnologies’ stronger consensus rating and higher possible upside, analysts clearly believe CollPlant Biotechnologies is more favorable than Pathfinder Cell Therapy.

Earnings and Valuation

This table compares CollPlant Biotechnologies and Pathfinder Cell Therapy”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CollPlant Biotechnologies	$10.96 million	4.25	-$7.02 million	($1.54)	-2.64
Pathfinder Cell Therapy	N/A	N/A	N/A	N/A	N/A

Pathfinder Cell Therapy has lower revenue, but higher earnings than CollPlant Biotechnologies.

Profitability

This table compares CollPlant Biotechnologies and Pathfinder Cell Therapy’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CollPlant Biotechnologies	-2,680.00%	-77.05%	-61.43%
Pathfinder Cell Therapy	N/A	N/A	N/A

Summary

CollPlant Biotechnologies beats Pathfinder Cell Therapy on 6 of the 10 factors compared between the two stocks.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.

About Pathfinder Cell Therapy

Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.